Showing results (2311-2320 of 3,034) with videos related to

Sort By:
Pageof 304
The Journal of Clinical Investigation|June 13, 1998
Protection from reoxygenation injury by inhibition of rac1K S Kim, K Takeda, R Sethi, et al.
Leukemia & Lymphoma|May 10, 2018
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myelomaShaji Kumar, Brian Durie, Hareth Nahi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2008
Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX studyAsher Chanan-Khan, Pieter Sonneveld, Michael W Schuster, et al.
Leukemia|April 26, 2017
Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomesP Hari, M-V Mateos, R Abonour, et al.
Journal of the American Society for Mass Spectrometry|January 16, 2020
Signature Fragment Ions of Biotinylated PeptidesSantosh Renuse, Anil K Madugundu, Jae Hun Jung, et al.
Iscience|January 5, 2026
The ionotropic AMPA receptor contributes to autoimmunity via altered regulatory T cell differentiationMarisa Mitchell-Flack, Makenzie Higgins, Ying Zheng, et al.
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
Journal of Continuing Education in Nursing|August 23, 2019
Using Systems Thinking to Implement the QSEN Informatics CompetencyJanet M Phillips, Ann M Stalter, Karen A Goldschmidt, et al.
Leukemia|February 11, 2017
RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myelomaE Viziteu, B Klein, J Basbous, et al.
BMC Cancer|April 14, 2005
Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759]H P Knaebel, A Märten, J Schmidt, et al.
Pageof 304